Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
New York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ:QLGN) ("Qualigen", "QLGN" or "Company"), a publicly-trading technology company majority owned by Faraday Future, today announced a strategic partnership with BitGo, the digital asset infrastructure company, to support its C10 treasury strategy, which accumulate and compound a market-cap-weighted basket of the world's top 10 crypto assets (excluding stablecoins).
Through this partnership, Qualigen will leverage BitGo's holistic treasury management offering1 that combines access to deep liquidity with secure qualified custody. BitGo's OTC desk will enable Qualigen to efficiently invest across a diversified basket of 10 digital assets marking a significant milestone in Qualigen's forward-looking treasury strategy.
Qualigen's treasury assets will be safeguarded by BitGo in secure, regulated cold storage with compliance protocols that meet the highest security standards. With over a decade of digital asset expertise, BitGo streamlined treasury management solution eliminates the complexities typically associated with institutional digital asset adoption allowing Qualigen to focus on its long-term vision for sustainable growth and digital integration.
"Qualigen has always stood at the intersection of innovation and technology," said Jerry Wang, Co-CEO at Qualigen. "Our partnership with BitGo allows us to further diversify our corporate treasury with digital assets, reflecting our commitment to both financial resilience and leadership in the evolving digital economy."
"We are proud to partner with Qualigen, a company that is redefining the future of mobility," said Mike Belshe, CEO at BitGo. "This $30 million multi-asset allocation demonstrates the growing confidence among enterprises in building a digital-first treasury strategy, and we are committed to providing the secure infrastructure and deep liquidity to make this vision possible."
This partnership highlights the accelerating convergence between cutting-edge technology and digital finance, positioning Qualigen as one of the first global technology innovators to adopt a diversified digital asset treasury strategy.
About BitGo
BitGo is the digital asset infrastructure company, delivering custody, wallets, staking, trading, financing, and settlement services from regulated cold storage. Since our founding in 2013, BitGo has been focused on accelerating the transition of the financial system to a digital asset economy. With a global presence and multiple regulated entities, BitGo serves thousands of institutions, including many of the industry's top brands, exchanges, and platforms, and millions of investors.
Services provided by BitGo and its affiliated entities.
Media Contact
[email protected]
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) is a biotechnology company headquartered in Carlsbad, California, focused on developing and commercializing innovative oncology and immunology therapeutics. The Company is actively pursuing crypto and web3 strategic initiatives that integrate advanced technologies and capital market innovation to accelerate global growth.
Investor & Media Contact
Investor Relations Department
Qualigen Therapeutics, Inc.
5857 Owens Avenue, Suite 300, Carlsbad, CA 92008
Tel: +1 (760) 452-8111
Email: [email protected]
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company may in some cases use terms such as "predicts," "believes," "potential," "continue," "anticipates," "estimates," "expects," "plans," "intends," "may," "could," "might," "likely," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. The Company's forward-looking statements are based on current beliefs and expectations of its management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the timing of the offering. Any or all of the forward-looking statements may turn out to be wrong or be affected by assumptions the Company makes that later turn out to be incorrect, or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the Company's ability to regain compliance with Nasdaq's continued listing requirements, including the Company's ability to file its Form 10-Q for the period ended September 30, 2024, or otherwise in the future, or otherwise maintain compliance with any other listing requirement of The Nasdaq Capital Market, the potential de-listing of the Company's shares from The Nasdaq Capital Market due to its failure to comply with the Nasdaq's continued listing requirement, or its alternatives, or otherwise in the future, and the other risks set forth in the Company's filings with the Securities and Exchange Commission, including in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by the Company's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Investor Relations
[email protected].
